News

AlgoDx recognized as one of the best startups in Sweden

October 20th, 2022.

AlgoDx has been recognized in the Swedish tech magazine Ny Teknik’s 33-listan, a long-running prestigious listing of the best technology start-ups in Sweden. Ny Teknik lists startups with international traction and potential to disrupt their respective industries. Read more here (in Swedish).

NAVOY® clinical trial abstract accepted at Society of Critical Care Medicine Congress in San Francisco, California

October 14th, 2022.

 An abstract with study result data from the largest randomised clinical trial ever conducted with a sepsis predictor in ICU has been accepted for presentation at the 2023 Society of Critical Care Medicine Congress. The SSCM Congress will be held January 21-24 in San Francisco, California. Read more here.

NAVOY® health economic model to be presented at ISPOR Europe 2022

September 28th, 2022.

3 hours earlier sepsis detection in ICU using NAVOY® and intervention with antibiotics leads to improved patient outcomes and reduced hospitalisation costs. Health economic research led by the Institute for Health Economics will be presented at Europe’s leading HE congress, ISPOR in Vienna November 6-9, 2022, poster title: The Potential Cost and Cost-Effectiveness Impact of Using Machine Learning Sepsis Prediction Algorithm for Early Detection of Sepsis in Intensive Care Units in Sweden and the United Kingdom. Read more here.

Real-world implementation of AlgoDx’s NAVOY® Sepsis nominated to the Athena Prize

Sep 15th, 2022.

The real-world integration of NAVOY Sepsis® with the ICUs at the Southern General Hospital in Stockholm has been nominated as finalist to the prestigious Athena Prize. The Athena Prize each year awards research and innovations created through collaboration between healthcare, academia and business. Read more here (in Swedish).

AlgoDx – Startup of the Year

June 30th, 2022.

AlgoDx has been awarded Best startup of the year by OVHcloud, a leading cloud computing provider. This prestigious award accentuates the cutting-edge technology that has been developed and deployed on the cloud by AlgoDx. Read more here.

NAVOY® Sepsis reduces the cost per ICU patient and will potentially have a substantial cost-saving and life-saving impact for ICU departments and health system.

April 26th, 2022.

Our paper “The Potential Cost and Cost-Effectiveness Impact of Using a Machine Learning Algorithm for Early Detection of Sepsis in Intensive Care Units in Sweden” has been published in Journal of Health Economics and Outcomes Research. Read more here.

Clinical validation of NAVOY® Sepsis in intensive care presented at the International Symposium on Intensive Care & Emergency Medicine

March 22nd, 2022.

Successful clinical validation results have been presented at the 41st International Symposium on Intensive Care & Emergency Medicine. In our prospective study, 304 intensive care patients (of which 44 patients had been diagnosed with Covid-19) were monitored using NAVOY® Sepsis during their ICU stay. The trial (NCT04570618) is the largest randomized clinical trial with a machine learning sepsis predictor ever conducted, and the first study that clinically validates a sepsis predictor against the Sepsis-3 criteria. Read more here.

NAVOY® Sepsis in real-world use at the Southern General Hospital

Feb 23rd, 2022.

Swedish National Public Radio has reported on the installation of NAVOY® Sepsis at the ICUs at Southern General Hospital in Stockholm, Sweden. Listen here (in Swedish).

AlgoDx partners with Takeda Pharma to develop IBD prediction algorithm for out-patient care

Feb 2nd, 2022.

Takeda is the initiator of the NOVA2 project aiming to transform patient care in inflammatory bowel disease, with patient-centric care through the use of a prediction algorithm developed by AlgoDx. Read more here.

AlgoDx gets late-breaking intensive care abstract accepted

Jan 25th, 2022.

AlgoDx announces that an abstract on clinical data of its ML-based sepsis predictor NAVOY® Sepsis has been accepted for a poster presentation at ISICEM. Read more here.

Uppsala University reports about the groundbreaking research lead by our Director of AI & Biostatistics,
Dr 
Inger Persson

Oct 28th, 2021.

Uppsala University narrates the story on how NAVOY® Sepsis was born, where a combination of AI and existing patient data helps healthcare professionals detect sepsis at an early stage. Read more here.

Proof-of-Concept Study of NAVOY® Sepsis published in JMIR

Oct 12th, 2021.

Our paper “A Machine Learning Sepsis Prediction Algorithm for Intended Intensive Care Unit Use (NAVOY Sepsis): Proof-of-Concept Study” has been published in JMIR Formative Research. Read more here.

The development of AlgoDx’s NAVOY® Sepsis nominated to the Athena Prize

Sep 18th, 2021.

AlgoDx’s clinical development programme for NAVOY Sepsis® has been nominated as finalist to the prestigious Athena Prize. The Athena Prize each year awards research and innovations created through collaboration between healthcare, academia and business. Read more here.

Completion of patient enrolment in clinical validation study of NAVOY® Sepsis

Sep 16th, 2021.

AlgoDx announces the completion of the patient enrolment in the world’s largest randomized clinical trial with a sepsis prediction algorithm (NCT04570618).

Meet Dr. Inger Persson, our Director AI & Biostatistics, at Vitalis eConference

May 18th, 2021.

Meet Dr Inger Persson, our Director AI & Biostatistics, who will be presenting at Vitalis eConference – Using Machine Learning To Predict Sepsis In Intensive Care. Read more here.

AlgoDx’s NAVOY® Sepsis gets CE mark for AI-powered sepsis prediction software

May 4th, 2021.

AlgoDx today announces the obtention of the CE mark for NAVOY® Sepsis. This medical device software is intended to assist medical staff at Intensive Care Units (ICU) to predict sepsis in adult ICU patients. Read press release here.

AlgoDx receives grant from Sweden’s Innovation Agency

April 28th, 2021.

AlgoDx receives the Innovative Startups grant by Vinnova aimed to develop scalable solutions that contribute to sustainable growth in a global market. This grant will allow AlgoDx to accelerate the development of the AlgoDx Cloud Platform for the integration of algorithm diagnostics and data-driven precision medicine in Electronic Health Record systems for Intensive Care. 

The round was led by Nascent Invest with participation from angel investors Tomas Mora-Morrison, co-founder of Cambio Healthcare Systems, and Fredrik Sjödin. The company intends to use the funds to continue to expand operations and its development efforts. Read press release here.

We are proud to see AlgoDx among the top startups of the 1st version of the European AI Startup Landscape, an initiative led by AI Sweden, UnternehmerTUM, Hub France AI, Ignite Sweden and RISE Research Institutes of Sweden with the objective to foster and accelerate AI in Europe. Check out the European AI Startup Landscape here.

AlgoDx today announces the obtention of regulatory approval from the Swedish Medical Products Agency to start a sepsis prediction study at an Intensive Care Unit in Sweden. The study has previously been approved by the National Ethics Committee through an expedited review for research that has potential to provide benefit for the treatment and prevention of Covid-19, given that sepsis is a common complication in connection with Covid-19. Read press release here.

Sweden’s Innovation Agency Vinnova has, through their SweLife and Medtech4Health programme, awarded 

a grant of 3 MSEK to AlgoDx together with Skåne University Hospital and Uppsala University. Read press release here.

AlgoDx raises pre-seed round

February 26th, 2020.

AlgoDx has closed a 6 MSEK pre-seed round led by Nascent Invest with participation from angel investor Fredrik Sjödin and Tomas Mora-Morrison, co-founder of Cambio Healthcare Systems.